Anaplasmosis vs. Lyme Disease: A Comparative Analysis

Anaplasmosis and Lyme disease are both transmitted by the same tick species, share overlapping geographic ranges, and peak during the same months, yet they are caused by fundamentally different microorganisms that invade different cell types, produce different symptoms, and require somewhat different diagnostic strategies. Lyme disease is caused by the spirochete bacterium Borrelia burgdorferi, while anaplasmosis is caused by Anaplasma phagocytophilum, an intracellular bacterium that targets white blood cells called neutrophils.¹ Understanding where these diseases overlap and where they diverge has real consequences for how quickly you get diagnosed and how your treatment unfolds.

Same Tick, Different Pathogens

Both infections are delivered by Ixodes scapularis (the blacklegged or deer tick) in the eastern and central United States, and by Ixodes pacificus on the West Coast. A single tick can carry both pathogens simultaneously, which is why co-infection is a recurring clinical problem. The shared vector is also why the two diseases track each other geographically: areas with high Lyme disease rates tend to report rising anaplasmosis cases as well. Anaplasmosis case counts in the U.S. have been climbing, driven in part by the expanding range of I. scapularis into new territory.²

Despite sharing a vehicle, the two pathogens behave very differently once they enter your body. Borrelia burgdorferi is a spirochete, a corkscrew-shaped bacterium that can disseminate from the skin into the bloodstream and from there into the joints, heart, and nervous system. Anaplasma phagocytophilum takes a more targeted approach, infecting neutrophils, the most abundant type of white blood cell in your blood. By setting up shop inside the very cells that are supposed to kill invading bacteria, it effectively hides from parts of the immune response.

How Transmission Speed Differs

One of the most practical differences between the two diseases is how quickly the tick needs to be attached before it can transmit the pathogen. For Lyme disease, the risk rises sharply after the tick has been feeding for about 48 to 72 hours. In one study from an endemic area, the infection rate among people whose ticks were attached for 72 hours or more was roughly 20%, compared to about 1% for shorter attachment times.³ That delay exists because Borrelia spirochetes reside in the tick’s midgut and need time to migrate to the salivary glands before they can be injected into the host.

Anaplasma phagocytophilum can be transmitted more quickly. While the exact minimum attachment time is harder to pin down in human studies, animal research suggests transmission can occur within 24 hours of attachment. This is a meaningful distinction: if you find and remove a tick within a day, your risk of Lyme disease drops substantially, but you may still have been exposed to Anaplasma if the tick was carrying it.

Both pathogens benefit from the tick’s own biochemistry. Tick saliva contains molecules that suppress the host’s local immune response at the bite site, a phenomenon researchers call saliva-assisted transmission.⁴ Lyme spirochetes have co-evolved with ticks to exploit these salivary molecules. One protein identified in Ixodes tick saliva directly blocks a key immune receptor, suppressing the host’s ability to fight off spirochetes as they enter the skin.⁵

Telling Them Apart by Symptoms

The single biggest clinical clue that separates the two diseases is the rash. Lyme disease is defined in its early stage by erythema migrans, the expanding red or “bull’s-eye” rash that appears at the tick bite site, usually within a few days to a month after the bite. This rash occurs in roughly 70 to 80 percent of confirmed Lyme cases and is considered distinctive enough to warrant treatment on its own, without waiting for lab results.

Anaplasmosis does not produce erythema migrans. In a direct comparison of culture-confirmed anaplasmosis patients and early Lyme disease patients, the rash was the defining feature that distinguished the two groups clinically.⁶ Anaplasmosis instead presents as an abrupt febrile illness: high fever, headache, muscle aches, and sometimes nausea. It can look a lot like the flu, especially during summer months when people are not expecting influenza. Blood work often shows low white blood cell counts, low platelet counts, and elevated liver enzymes, a combination of abnormalities that can help point toward the diagnosis when the clinical picture is otherwise vague.

Without the rash to guide them, doctors sometimes miss anaplasmosis early on or mistake it for a viral illness. This matters because severe anaplasmosis can lead to organ damage, respiratory failure, or secondary infections, particularly in older adults and people with weakened immune systems. Lyme disease, left untreated, follows a different trajectory: it can progress over weeks to months into joint inflammation, nerve problems, or cardiac conduction abnormalities.

Diagnostic Challenges

The diagnostic workup for the two infections is quite different. For Lyme disease, the standard approach is a two-tier serologic test: an initial screening test followed by a confirmatory test looking for antibodies against Borrelia. The catch is that antibodies take time to develop, so testing too early in the illness can produce a false negative. In the first couple of weeks after a tick bite, the rash is a more reliable indicator than the blood test.

Anaplasmosis is trickier. Antibody tests for anaplasmosis have the same early-window problem, and the disease often makes people sick enough to seek care before antibodies are detectable. PCR testing, which looks for the pathogen’s DNA in the blood, has proven to be the most useful early diagnostic tool for anaplasmosis. A study evaluating different diagnostic methods found that PCR had high specificity (essentially no false positives) and reasonable sensitivity for catching active infections. Serology performed better when both acute and follow-up blood samples were available, which is less useful for making treatment decisions in the moment.⁷ Examining a blood smear under the microscope can also reveal clusters of Anaplasma organisms inside neutrophils, though this method misses many cases.

The practical takeaway is that if you develop a sudden high fever after a tick bite in an endemic area and you do not have a rash, your doctor should consider anaplasmosis early and potentially order a PCR test rather than relying solely on serology.

Treatment Overlap and Differences

Here is where the two diseases converge in a useful way: doxycycline treats both. For early Lyme disease, a course of doxycycline, amoxicillin, or cefuroxime axetil is effective, with doxycycline being the most commonly prescribed in adults. For anaplasmosis, doxycycline is essentially the only recommended oral option, and evidence supports a 10-day course for typical cases.⁸

This overlap is clinically convenient, especially in situations where a doctor suspects a tick-borne illness but is not yet sure which one. Starting doxycycline covers both bases. However, the overlap creates a gap for certain patients. Children under eight and pregnant women are typically steered away from doxycycline because of concerns about tooth staining and fetal effects. For Lyme disease, amoxicillin is a well-established alternative. For anaplasmosis, no alternative oral antibiotic has been proven to work reliably, which puts these patient groups in a difficult spot. In practice, short courses of doxycycline are now considered acceptable even in young children when a serious tick-borne illness is suspected, but the decision involves weighing risks more carefully than it does for Lyme disease alone.

For more advanced Lyme disease involving the nervous system or heart, intravenous ceftriaxone is the standard escalation. Anaplasmosis rarely requires parenteral antibiotics because it responds quickly to doxycycline when caught in time. Most people with anaplasmosis improve within 24 to 48 hours of starting treatment, which is faster than the typical response in Lyme disease.

When You Get Both at Once

Because the same tick can carry both pathogens, co-infection is a real phenomenon, not just a theoretical concern. Among patients presenting with erythema migrans (the Lyme disease rash), co-infection with anaplasmosis was found in anywhere from about 2% to 10% of cases, depending on how co-infection was defined.⁹ That range sounds wide, and it is. The variation comes down to whether researchers require a positive PCR, a positive antibody test, or both to call it co-infection.

An interesting finding from that same research is that co-infected patients did not always do worse than those with Lyme disease alone. In fact, high fever and abnormal blood counts, the hallmarks of standalone anaplasmosis, were less common in co-infected patients than in those with anaplasmosis by itself. One interpretation is that the immune response triggered by one infection may partially modulate the other, though the mechanisms behind this are not well understood. Regardless, the practical point stands: if you have confirmed Lyme disease and your doctor is treating with doxycycline, any concurrent anaplasmosis is likely being treated at the same time.

How Each Pathogen Evades Your Immune System

Anaplasma phagocytophilum has an immune evasion strategy that is, frankly, audacious. It infects neutrophils, which are your body’s frontline antimicrobial cells, and then prevents those neutrophils from dying on schedule. Neutrophils are naturally short-lived; they circulate for a few hours, do their job, and then undergo programmed cell death. A. phagocytophilum blocks this self-destruct program by keeping the cell’s mitochondria intact and suppressing the activation of enzymes that would normally trigger cell death.¹⁰ The bacterium also boosts production of a survival protein inside the neutrophil, keeping its host cell alive long enough for the pathogen to replicate.¹¹ Additional research has shown that the bacterium activates a specific stress-response signaling pathway in the neutrophil that further delays cell death.¹²

The net effect is a bacterium that hijacks the immune cell meant to destroy it, extends that cell’s lifespan, and uses it as a protected replication factory. This strategy also explains why anaplasmosis causes drops in white blood cell counts: functional neutrophils become compromised, and the overall immune response becomes less effective at controlling other infections.

Borrelia burgdorferi uses a different playbook. Rather than hiding inside immune cells, it evades the immune system by continuously varying its surface proteins, making it harder for antibodies to lock on. It also moves into tissues like joints and connective tissue where immune surveillance is less active. The spirochete’s ability to cross the blood-brain barrier and enter the nervous system accounts for the neurological complications seen in later-stage Lyme disease.

Seasonal Timing and When to Worry

Both diseases follow a seasonal pattern tied to the life cycle of Ixodes ticks. In the upper Midwest, where both diseases are common, nymphal ticks (the life stage most responsible for transmitting disease to humans) are most active from May through August, with a peak typically in June. Adult ticks are active over a longer season, with a spring peak in April and a smaller, less consistent peak in October.¹³ The nymphal peak aligns with the typical surge in reported human Lyme disease and anaplasmosis cases.

Nymphs are the more dangerous life stage for disease transmission because they are small enough to go unnoticed on the skin for longer. An adult tick is about the size of a sesame seed when unfed and is easier to spot and remove before it transmits infection. A nymphal tick is closer to the size of a poppy seed and can feed for a day or more before you even feel it. Given the shorter attachment time needed for Anaplasma transmission, this makes nymph season especially relevant for anaplasmosis risk.

The Economic and Public Health Picture

Lyme disease is by far the more commonly reported of the two, with an estimated 476,000 cases diagnosed and treated annually in the United States according to CDC analyses. Anaplasmosis case counts are much lower in absolute terms but have been rising steeply, with thousands of cases reported each year and likely more going undiagnosed due to the nonspecific presentation.

The financial burden of Lyme disease has been formally studied. A multi-site investigation of diagnosed Lyme disease in high-incidence areas found that the average societal cost per patient was roughly $2,000, with patients who had disseminated disease costing approximately double those with localized disease. Aggregated nationally, the annual cost of diagnosed Lyme disease could range from $345 million to $968 million.¹⁴ Comparable economic analyses for anaplasmosis alone are scarce, partly because case volumes are smaller and partly because the disease is often lumped with other tick-borne illnesses in cost studies. However, severe anaplasmosis cases that require hospitalization or ICU care can generate substantial individual costs, particularly among older adults.

Transmission Beyond the Tick Bite

Lyme disease is considered a vector-borne illness with no meaningful non-tick transmission routes. You cannot get it from a blood transfusion, an organ transplant, or casual contact with an infected person. Anaplasma phagocytophilum, on the other hand, has a documented track record of transmission through blood products and organ transplantation. A review of U.S. cases identified 132 instances of ehrlichiosis or anaplasmosis among transfusion and transplant recipients from 1997 through 2020, including 12 cases specifically linked to blood transfusions.¹⁵

This is a small number in the context of millions of transfusions per year, but it matters because transplant and transfusion recipients are often immunocompromised, making them especially vulnerable to severe disease. There is currently no routine screening of donated blood for Anaplasma. Awareness of this transmission route is most relevant for patients who develop unexplained fever and low blood counts after receiving blood products or an organ, particularly during tick season in endemic areas.

How Anaplasmosis Was Recognized as a Human Disease

Lyme disease was formally identified in the mid-1970s following a cluster of arthritis cases among children in Lyme, Connecticut. The story of anaplasmosis is less well known. The bacterium that causes it was originally described in the 1930s in Scotland as the cause of “tick-borne fever” in sheep, and related organisms were identified in horses and dogs in the United States in the 1960s and 1970s. For decades, these were considered strictly veterinary pathogens. It was not until 1994 that human granulocytic anaplasmosis was recognized in the United States, when patients in Wisconsin and Minnesota developed febrile illnesses after tick bites and the causative agent was identified in their neutrophils.¹⁶ The organism was originally classified under the genus Ehrlichia and was renamed Anaplasma phagocytophilum after a taxonomic reorganization unified three previously separate species of granulocytic bacteria.

This relatively recent recognition as a human pathogen helps explain why anaplasmosis still gets less public attention than Lyme disease. Lyme has had nearly 50 years of public health messaging, patient advocacy, and media coverage. Anaplasmosis, despite its increasing incidence and potential severity, remains less familiar to both the public and to many primary care physicians outside of heavily endemic areas.

What Happens After Recovery

The long-term trajectories of the two diseases differ in ways that affect patients’ expectations. Anaplasmosis, when treated with doxycycline, typically resolves completely. Chronic or relapsing anaplasmosis is extremely rare in people with intact immune systems. The acute illness can be miserable and occasionally life-threatening, but the infection generally clears without lingering consequences.

Lyme disease is more complicated. Most patients treated early recover fully, but a subset of patients, often estimated at 10 to 20 percent of those treated for Lyme disease, report persistent symptoms such as fatigue, pain, and cognitive difficulties for months or even years afterward. This condition, often called post-treatment Lyme disease syndrome, remains one of the most contentious areas in infectious disease medicine. The debate centers on whether persistent symptoms reflect ongoing infection, an autoimmune aftermath triggered by the original infection, or a separate process entirely. Whatever the mechanism, the experience is real for the patients involved and distinguishes Lyme disease from anaplasmosis in terms of long-term burden.

For co-infected patients, recovery patterns largely follow the more dominant infection. If anaplasmosis is caught and treated early, the Lyme component tends to determine the longer-term clinical picture. Clinicians in endemic areas increasingly test for both pathogens when a patient presents with a tick-borne illness, since missing a co-infection can delay resolution of symptoms even when the primary diagnosis is being treated appropriately.